Literature DB >> 6553057

Kinin release from high molecular weight kininogen by the action of Hageman factor in the absence of kallikrein.

R C Wiggins.   

Abstract

Proteolysis of 125I-high molecular weight (Mr) kininogen occurred in kaolin-activated plasma which was deficient in prekallikrein, but not in plasma which lacked both prekallikrein and Hageman factor (HF) activity. The implication of this observation is that HF itself might be capable of releasing kinin from high Mr kininogen. This concept was further supported by the following studies. In a purified protein system rabbit (Mr = 80,000) two-chain activated HF (alpha-HFa) incubated with human 125I-high Mr kininogen caused rapid proteolysis of the kininogen in the presence, but not in the absence, of kaolin. This was in contrast to the effect of kallikrein on proteolysis of high Mr kininogen which was inhibited 10-fold by the presence of kaolin. The possibilities that the alpha-HFa preparation was contaminated by rabbit kallikrein or that the human high Mr kininogen preparation was contaminated by human prekallikrein were excluded by using specific antibodies (IgG) against these proteins. The proteolytic fragments of 125I-high Mr kininogen generated by both alpha-HFa and kallikrein were indistinguishable by sodium dodecyl sulfate-polyacrylamide gel analysis. Bioassayable kinin was released from high Mr kininogen following incubation with alpha-HFa in the presence of kaolin. The amount of kinin released in proportion to the extent of proteolysis was the same for both kallikrein and alpha-HFa. The data show that activated Hageman factor may cause release of kinin by proteolytic cleavage of high Mr kininogen. This phenomenon occurs not only in a purified system of proteins but also in kaolin-activated plasma.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6553057

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  The sequence HGLGHGHEQQHGLGHGH in the light chain of high molecular weight kininogen serves as a primary structural feature for zinc-dependent binding to an anionic surface.

Authors:  R A DeLa Cadena; R W Colman
Journal:  Protein Sci       Date:  1992-01       Impact factor: 6.725

2.  A critical role for plasma kallikrein in the pathogenesis of autoantibody-induced arthritis.

Authors:  Aizhen Yang; Junsong Zhou; Bo Wang; Jihong Dai; Robert W Colman; Wenchao Song; Yi Wu
Journal:  FASEB J       Date:  2017-08-14       Impact factor: 5.191

3.  Serum stimulation of CCR7 chemotaxis due to coagulation factor XIIa-dependent production of high-molecular-weight kininogen domain 5.

Authors:  Manish P Ponda; Jan L Breslow
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-24       Impact factor: 11.205

Review 4.  Surface-mediated defense reactions. The plasma contact activation system.

Authors:  R W Colman
Journal:  J Clin Invest       Date:  1984-05       Impact factor: 14.808

5.  Prolylcarboxypeptidase independently activates plasma prekallikrein (fletcher factor).

Authors:  J Wang; A Matafonov; H Madkhali; F Mahdi; D Watson; A H Schmaier; D Gailani; Z Shariat-Madar
Journal:  Curr Mol Med       Date:  2014       Impact factor: 2.222

6.  Cleavage of human high molecular weight kininogen markedly enhances its coagulant activity. Evidence that this molecule exists as a procofactor.

Authors:  C F Scott; L D Silver; M Schapira; R W Colman
Journal:  J Clin Invest       Date:  1984-04       Impact factor: 14.808

7.  Protection by recombinant alpha 1-antitrypsin Ala357 Arg358 against arterial hypotension induced by factor XII fragment.

Authors:  M Schapira; M A Ramus; B Waeber; H R Brunner; S Jallat; D Carvallo; C Roitsch; M Courtney
Journal:  J Clin Invest       Date:  1987-08       Impact factor: 14.808

8.  Differential processing of high-molecular-weight kininogen during normal pregnancy.

Authors:  Stephenie H Droll; Yen-Michael Sheng Hsu; Steven K Drake; Ashley Kim; Weixin Wang; Katherine R Calvo; Zheng Cao; Tony Y Hu; Zhen Zhao
Journal:  Rapid Commun Mass Spectrom       Date:  2020-02-11       Impact factor: 2.586

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.